137375-82-7

Usage

Uses

Used in Pharmaceutical Industry:
3-(Ethylsulfinyl)propanoic acid is used as a pharmaceutical intermediate for the synthesis of various drugs. Its unique structure, containing a sulfoxide group, may offer potential applications in the development of new therapeutic agents.
Used in Chemical Research:
3-(Ethylsulfinyl)propanoic acid serves as a subject of study in chemical research, particularly in the field of organic chemistry. Its properties and reactivity can be investigated to understand the behavior of sulfenic acids and their derivatives, contributing to the broader knowledge of chemical compounds.
Used in Material Science:
3-(Ethylsulfinyl)propanoic acid may be utilized in material science for the development of new materials with specific properties. Its incorporation into polymers or other compounds could lead to materials with unique characteristics, such as improved stability or reactivity.

InChI:InChI=1/C5H10O3S/c1-2-9(8)4-3-5(6)7/h2-4H2,1H3,(H,6,7)

Upstream product

• 7244-82-8 3-(ethylthio)propanoic acid 

Downstream Products

• 85390-19-8 N-{2-[4-(3-Cyclohexyl-2-imino-imidazolidine-1-sulfonyl)-phenyl]-ethyl}-3-ethanesulfinyl-propionamide 

Relevant academic research and scientific papers

Soft-enolization Baker-Venkataraman Rearrangement Enabled Total Synthesis of Dirchromones and Related 2-Substituted Chromones

A seven-step total synthesis of the original scaffold of cytotoxic dirchromones involving an unprecedented soft-enolization Baker-Venkataraman rearrangement was designed. The methodology enabled access to naturally occurring dirchromone 1 (21% overall yield) at gram-scale, which was screened for cytotoxicity against 13 cancer cell lines. The scope of the soft-enolization Baker-Venkataraman rearrangement encompasses diversely substituted dirchromones, including flavonoids, 2-styrylchromones, and 2-phenylethylchromones.

Cis-platinum complexes with chelating amines and sulphinyl carboxylates

STR1 Platinum (II) complexes of formula (I) where: Am is a monodentate amine, or (Am)2 is a bidentate amine, B represents a straight or branched alkyl residue or a single bond, R is selected from the group of hydrogen, (C3 -C8) cycloalkyl, phenyl or naphthyl which may be substituted by halogens (I, Br, Cl, F), trihalomethane, hydroxyl, (C1 -C4)-alkoxyl, (C1 -C7)-acylamino, (C1 -C7)-sulphamido, allyl, phenoxyl, haloalkoxyl, nitro, cyano, azido, with condition that when R is hydrogen B is different from a single bond, Q is a residue of formula --(CH2)n1 --CRa Rb --(CH2)n2 --, 1,2- or 2,3-naphthalene, benzo-1,3-dioxolan-5,6-diyl, substituted or unsubstituted 1,2-phenylene, Ra and Rb are selected independently of each other from the group of hydrogen, allyl, linear or branched (C1 -C8)-alkyl, --(CH2)p OH, --(CH2 CH2 O)q --CH3, or taken together with the carbon atom to which they are bonded form a (C3 -C8) cycloalkyl, or heterocyclic tetrahydropyran-4,4-diyl, n1 and n2 are independently zero or the integer 1, p is an integer from 2 to 6, and q is an integer from 1-3, X- is a biocompatible anion such as chloride, bromide, iodide, nitrate, perchlorate, or one equivalent of sulphate or phosphate, or an anion of a monovalent C1 -C4 organic acid such as acetate, propionate or chloroacetate, or of an aromatic acid such as benzoate, or of a heteroaromatic acid such as nicotinate are described. The compounds are useful as anti-tumor drugs.